- Home
- IPSC vs ONCY Comparison
IPSC vs ONCY Comparison
Compare IPSC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- ONCY
- Stock Information
- Founded
- IPSC 2019
- ONCY 1998
- Country
- IPSC United States
- ONCY Canada
- Employees
- IPSC N/A
- ONCY N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- ONCY Pharmaceuticals and Biotechnology
- Sector
- IPSC Health Care
- ONCY Health Care
- Exchange
- IPSC Nasdaq
- ONCY Nasdaq
- Market Cap
- IPSC 62.1M
- ONCY 56.2M
- IPO Year
- IPSC 2021
- ONCY 1999
- Fundamental
- Price
- IPSC $0.73
- ONCY $0.73
- Analyst Decision
- IPSC Strong Buy
- ONCY Strong Buy
- Analyst Count
- IPSC 5
- ONCY 2
- Target Price
- IPSC $11.00
- ONCY $4.00
- AVG Volume (30 Days)
- IPSC 493.4K
- ONCY 564.7K
- Earning Date
- IPSC 03-13-2025
- ONCY 03-06-2025
- Dividend Yield
- IPSC N/A
- ONCY N/A
- EPS Growth
- IPSC N/A
- ONCY N/A
- EPS
- IPSC N/A
- ONCY N/A
- Revenue
- IPSC $2,684,000.00
- ONCY N/A
- Revenue This Year
- IPSC $230.60
- ONCY N/A
- Revenue Next Year
- IPSC $31.83
- ONCY N/A
- P/E Ratio
- IPSC N/A
- ONCY N/A
- Revenue Growth
- IPSC 7.88
- ONCY N/A
- 52 Week Low
- IPSC $0.68
- ONCY $0.67
- 52 Week High
- IPSC $5.51
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- IPSC 30.98
- ONCY 40.10
- Support Level
- IPSC $0.72
- ONCY $0.71
- Resistance Level
- IPSC $0.82
- ONCY $0.79
- Average True Range (ATR)
- IPSC 0.06
- ONCY 0.04
- MACD
- IPSC 0.01
- ONCY 0.00
- Stochastic Oscillator
- IPSC 27.43
- ONCY 32.71
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.